HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis.

Abstract
Teriflunomide is a once-daily oral immunomodulatory agent recently approved in the United States for the treatment of relapsing multiple sclerosis (RMS). This study investigated neurophysiological deficits in descending spinal cord motor tracts during experimental autoimmune encephalomyelitis (EAE; a model of multiple sclerosis) and the functional effectiveness of prophylactic or therapeutic teriflunomide treatment in preventing the debilitating paralysis observed in this model. Relapsing-remitting EAE was induced in Dark Agouti rats using rat spinal cord homogenate. Animals were treated with oral teriflunomide (10 mg/kg daily) prophylactically, therapeutically, or with vehicle (control). Transcranial magnetic motor-evoked potentials were measured throughout the disease to provide quantitative assessment of the neurophysiological status of descending motor tracts. Axonal damage was quantified histologically by silver staining. Both prophylactic and therapeutic teriflunomide treatment significantly reduced maximum EAE disease scores (P < 0.0001 and P = 0.0001, respectively) compared with vehicle-treated rats. Electrophysiological recordings demonstrated that both teriflunomide treatment regimens prevented a delay in wave-form latency and a decrease in wave-form amplitude compared with that observed in vehicle-treated animals. A significant reduction in axonal loss was observed with both teriflunomide treatment regimens compared with vehicle (P < 0.0001 and P = 0.0014, respectively). The results of this study suggest that therapeutic teriflunomide can prevent the deficits observed in this animal model in descending spinal cord motor tracts. The mechanism behind reduced axonal loss and improved motor function may be primarily the reduced inflammation and consequent demyelination observed in these animals through the known effects of teriflunomide on impairing proliferation of stimulated T cells. These findings may have significant implications for patients with RMS.
AuthorsDeborah Iglesias-Bregna, Susan Hanak, Zhongqi Ji, Margaret Petty, Li Liu, Donghui Zhang, Kathleen McMonagle-Strucko
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 347 Issue 1 Pg. 203-11 (Oct 2013) ISSN: 1521-0103 [Electronic] United States
PMID23892570 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Crotonates
  • Hydroxybutyrates
  • Nitriles
  • Toluidines
  • teriflunomide
Topics
  • Animals
  • Crotonates (pharmacology, therapeutic use)
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental (physiopathology, therapy)
  • Evoked Potentials, Motor (drug effects, physiology)
  • Hydroxybutyrates
  • Male
  • Nitriles
  • Rats
  • Toluidines (pharmacology, therapeutic use)
  • Transcranial Magnetic Stimulation (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: